BIOALVO SA FILED PATENTS COVERING FIRST DRUG PRODUCTS
26 June 2008
Showing the efficacy of its HTS screening systems and successful collaboration with Academia, Bioalvo managed to file its first IP on products eight months after having the technology platform up and running. Bioavlo filed two PCT patent applications covering the therapeutic use of a compound identified using its proprietary drug screening technology, already protected by two earlier filed PCT applications.
Relevant data regarding toxicity, efficacy and physiological behaviour (like ability to cross the blood brain barrier – BBB), that were key information for the IP filing, were obtained under the aegis of a successful collaboration with Professor Miguel Castanho's team at UL.
The PCTs were filed covering therapeutic use for indications such as pain and CNS diseases.
Bioalvo acquired full commercial and IP rights regarding the products to UL, who will receive royalties on Bioalvo's net revenues regarding the product sales. The relevance of the existing data already attracted the attention of key international players in the fields of pain and CNS.
Helena Vieira, Bioalvo's CEO said, "We are very happy we've been able to show that industry and academia can work quite well together in Portugal and that is the way to value the good science we have within our universities. Filing our first IP around products give us a great feeling of accomplishment since this is a relevant landmark in the planned roadmap for the company development. These are the first of many that will follow, technology is up and running successfully as we have reassured with this IP filing, so it is only a question of time and resources."
Luis Amado, Bioalvo's CBDO mentioned, "Having products with relevant data as in this case is a great asset to foster partnerships and licensing deals, not only on product front but also for the use of technology that can see its value considerably increased by those."
Professor Miguel Castanho declared, "this is an important step in technology transfer and industry-academia partnerships in Portugal. It is certainly an encouraging event to cross the old boundaries that still separate the two sectors. It is also inspiring to have the perspective that our academic work may one day revert in direct favour of suffering patients. Without a strong and committed industrial partner like Bioalvo this goal would be elusive.
About Bioalvo S.A.
Bioalvo is the first Portuguese biotech company working on early stages of drug discovery.
Bioalvo designs and develops innovative drug development programmes that generate potent and efficient drugs aimed at central nervous system and neurodegenerative disorders.
Through its proprietary innovative platforms Bioalvo can accelerate and increase the efficiency of drug discovery through HTS and generate true and potent drug candidates for its pipeline and of its partners that will ultimately lead to treatments and cures for human diseases with dramatic social impacts such as amyloidosis, Huntington's, Alzheimer's, Parkinson's or cancer. The company operates an alliance-based R&D business model and relies on partnerships to fill its pipeline and bring its products to the market.
Bioalvo is fully committed in building value by developing a diverse pipeline of products to address un-met healthcare needs.
